MBB Public Markets I LLC Invests $313,000 in Zoetis Inc. $ZTS

MBB Public Markets I LLC bought a new position in Zoetis Inc. (NYSE:ZTS) during the 1st quarter, HoldingsChannel reports. The fund bought 1,900 shares of the company’s stock, valued at approximately $313,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Ascent Group LLC lifted its stake in shares of Zoetis by 18.8% in the first quarter. Ascent Group LLC now owns 26,276 shares of the company’s stock worth $4,326,000 after buying an additional 4,158 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. lifted its stake in shares of Zoetis by 2.7% in the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 40,228 shares of the company’s stock worth $6,624,000 after buying an additional 1,047 shares in the last quarter. Caxton Associates LLP bought a new position in shares of Zoetis in the first quarter worth approximately $930,000. Sciencast Management LP lifted its stake in shares of Zoetis by 148.7% in the first quarter. Sciencast Management LP now owns 21,474 shares of the company’s stock worth $3,536,000 after buying an additional 12,838 shares in the last quarter. Finally, Voleon Capital Management LP lifted its position in Zoetis by 255.7% during the first quarter. Voleon Capital Management LP now owns 56,975 shares of the company’s stock valued at $9,381,000 after purchasing an additional 40,959 shares during the period. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ZTS shares. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and lowered their price objective for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Finally, Argus restated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday. Five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Zoetis has a consensus rating of “Moderate Buy” and a consensus price target of $200.88.

Zoetis Stock Down 1.3%

ZTS opened at $149.80 on Wednesday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a market capitalization of $66.39 billion, a PE ratio of 25.78, a PEG ratio of 2.44 and a beta of 0.88. The firm’s 50 day simple moving average is $152.90 and its two-hundred day simple moving average is $157.61.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period last year, the firm earned $1.56 earnings per share. The company’s quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.